Welcome to ourH1 Report 2020

We ended the first half of 2020 with a strong cash balance, positioning us well to further grow our pipeline and deliver.

Financial highlights

Group revenues

€224.6 million

At a glance

Cash position

€5566.5 million

At a glance

Deferred income

€2823.8 million

At a glance

R&D expenditure

€265.9 million

At a glance

Letter from the management

Receiving a positive CHMP opinion is a key step toward delivering on our promise to become a fully-integrated biopharma company. Onno van de Stolpe, CEO
Letter from the management